1. Preoperative evaluation for aortic surgery Inter-hospital Conference 2 (2/2554) Aortic surgery: Update & Decision making วันเสาร์ที่ 17 กันยายน 2554 ห้องประชุมสมาคมศิษย์เก่าแพทย์ศิริราช โรงพยาบาลศิริราช นพ. วันชัย วงศ์กรรัตน์

2. Acute aortic syndrome 1.Aortic dissection 2.Intramural Hematoma 3.Penetrating Atherosclerotic Ulcer 4.Pseudoaneurysms of the Thoracic Aorta 5.Traumatic Rupture of the Thoracic Aorta

3. Acute aortic syndrome

4. Acute surgical management pathway Step 1 Determine suitable for surgery Step 2 Determine stability for preop testing Ascending Aortic dissection by imaging Is pt a suitable candidate for Sx?Medical Tx Is pt stable enough to allow pre-op testing? Age > 40 yr Assess need for preop CAG Known CAD? Significant risk factors for CAD? Significant CAD by angiography? Plan for CABG if appropriate at time of AoD repair Step 3 Determine likelihood of coexistent CAD yes no

5. Step 4 Intraoperative evaluation of aortic valve Urgent operative management Intra operative assessment of aortic valve by TEE Aortic regurgitation? or Dissection of aortic sinuses? Step 5 Surgical intervention Graft replacement of ascending aorta +/- aortic arch and repair/ replacement of aortic valve or aortic root Graft replacement of ascending aorta +/- aortic arch no yes

6. Acute aortic syndrome

7. 1.Perfusion Deficits and End-Organ Ischemia 2.Acute aortic regurgitation 3.Myocardial Ischemia or Infarction 4.Heart Failure and Shock 5.Pericardial Effusion and Tamponade 6.Syncope 7.Neurologic Complications 8.Pulmonary Complications 9.Gastrointestinal Complications

9. Acute aortic syndrome BP and HR 71% type B, 36% type A  hypertension 20%  hypotension ( cardiac tamponade, aortic hemorrhage, severe AR, MI) Measure BP in both arms and legs

10. Evaluation and Management of Acute Thoracic Aortic Disease Recommendations for Estimation of Pretest Risk ofThoracic Aortic Dissection Class I 1.specific questions about medical history, family history, and pain features as well as a focused examination to identify findings that are associated with aortic dissection,

11. High risk conditions and historical features Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, Turner syndrome, or other connective tissue disease. Patients with mutations in genes known to predispose to thoracic aortic aneurysms and dissection, such as FBN1, TGFBR1, TGFBR2, ACTA2, and MYH11. Family history of aortic dissection or thoracic aortic aneurysm. Known aortic valve disease. Recent aortic manipulation (surgical or catheter-based). Known thoracic aortic aneurysm. High risk chest, back, abdomianl pain features Pain that is abrupt or instantaneous in onset. Pain that is severe in intensity. Pain that has a ripping, tearing, stabbing, or sharp quality. High risk examination features Pulse deficit. SBP limb differential > 20 mm Hg. Focal neurologic deficit. Murmur of AR (new).

12. Evaluation and Management of Acute Thoracic Aortic Disease Laboratory testing D-dimer - venous thromboembolism, sepsis, DIC, malignancies, recent trauma or surgery, and acute MI Pre-surgical screening CBC, serum chemistry, coagulation profiles, blood type and screen

13. Evaluation and Management of Acute Thoracic Aortic Disease Recommendations for Screening Tests Class I ECG – all patients CXR( intermediate and low risk) Urgent and definitive imaging of the aorta using TEE, CT, MRI is recommended to identify or exclude thoracic aortic dissection in pts at high risk for the disease by initial screening. Class III A negative chest x-ray should not delay definitive aortic imaging in patients determined to be high risk for aortic dissection by initial screening.

14. Evaluation and Management of Acute Thoracic Aortic Disease Recommendations for Diagnostic Imaging study Class I 1. Selection of a specific imaging modality to identify or exclude aortic dissection should be based on patient variables and institutional capabilities, including immediate availability 2.If a high clinical suspicion exists for acute aortic dissection but initial aortic imaging is negative, a second imaging study should be obtained.

15. Evaluation and Management of Acute Thoracic Aortic Disease Recommendations for initial management Class I 1.Control HR and BP a. iv beta blockade  titrated target HR of ≤ 60 bpm or less. b. In pts with r contraindications to beta blockade, nondihydropyridine calcium channel blocking agents should be used as an alternative for rate control. c. If SBP ≥ 120 mm Hg after adequate HR control has been obtained, then ACEI and/or other vasodilators should be administered intravenously to further reduce BP that maintains adequate end- organ perfusion. d. Beta blockers should be used cautiously in the setting of acute AR because they will block the compensatory tachycardia. Class III Vasodilator therapy should not be initiated prior to rate control so as to avoid associated reflex tachycardia that may increase aortic wall stress, leading to propagation or expansion of a AoD

16. Evaluation and Management of Acute Thoracic Aortic Disease Recommendations for definite management Class I 1.Urgent sx consultation should be obtained for all patients diagnosed with thoracic AoD regardless of the anatomic location (ascending versus descending) as soon as the diagnosis is made or highly suspected. 2.Acute thoracic AoD the ascending aorta should be urgently evaluated for emergent surgical repair because of the high risk of associated life-threatening complications such as rupture 3. Acute thoracic AoD involving the descending aorta should be managed medically unless life-threatening complications develop (eg, malperfusion syndrome, progression of dissection, enlarging aneurysm, inability to control blood pressure or symptoms)

17. AoD evaluation pathway Consider Acute AoD in all pt presenting with Chest, back, abdominal pain Syncope Symptom consistent with perfusion deficit + High risk conditions Marfan syndrome CNT disease Fm hx of AoD. Known AV disease. Recent aortic manipulation Known thoracic aortic aneurysm High risk pain features chest, back, abdomianl abrupt in onset. severe in intensity ripping, tearing stabbing sharp quality High risk exam features Pulse deficit. SBP limb diferential > 20 mm Hg. Focal neurologic deficit. Murmur of AR (new) Determine pre-test risk by combination of risk condition, history, exam + + Step 1 Identify patient at Risk For acute AoD Step 2 Bedside risk assessment

18. yes intermediate risk Any single high risk features High risk ≥2 high risk features Proceed with diagnostic Evaluation as clinically indicated by presentation Alternative diagnosis identified Initiate appropiate Tx Unexplained hypotension or widened mediastinum Consider Ao imaging Immediate Sx consult and imaging ECG: STEMI CXR : clear alternate Dx Primary ACS : reperfusion Tx Initiate appropriate tx Clinical suggest alternate Dx Alternate Dx confirm by other further testing Expedited Ao imaging TEE, MRI, CT Step 3 Risk based diagnostic evaluation Low risk No high risk features yes no yes

19. Step 4 Acute AoD Identified of excluded Aortic dissection present Proceed to treatment pathway If high clinical suspicious AoD exists, consider secondary imaging study yes no

20. Once the diagnosis of AoD or one of its anatomic variants (IMH or PAU) is obtained, initial management is directed at limiting propagation of the false lumen by controlling aortic shear stress while simultaneously determining which patients will benefit from surgical or endovascular repair Initial management

21. Blood Pressure and Rate Cont targets HR <60 bpm SBP 100-120 mmHg Pain control Hypotension : volume replacement, immediate operation For patients with hemopericardium and cardiac tamponade who cannot survive until surgery, pericardiocentesis can be performed by withdrawing just enough fluid to restore perfusion Determine definite tx

22. Acute AoD management pathway. Arrange for definite Tx Appropriate Sx consultation Step 1 Immediate post diagnosis management

23. obtain accurate BP prior to beginning Tx Measure in both arms Step 2 Innitial management aortic wall stress hypotension/shock stage Anatomic based management Intravenous rate and pressure control iv beta blocker / calcium channel blocker (HR < 60 bpm) Pain control iv opiate SBP > 120 mmHg Secondary pressure Control Intravenous vasodilator (SBP < 120 mmHg) Type A dissection Type B dissection Urgent Sx consult Intravenous fluid bolus titrate to MAP 70 mmHg Or Euvolemia Review imaging tamponade contained rupture severe AR Intravenous fluid bolus titrate to MAP 70 mmHg Or Euvolemia Evaluate etiology Of hypotension contained rupture cardiac function Urgent Sx consult Etioligy of hypotension amenable to operative management Yes No

24. Step 3 Definite management ongoing medical Tx Operative or Intervational management Complication requiring Operative or Intervational management Malperfusion syndrome Progression of dissection Aneurysm expansion Uncontrolled hypertension Yes No Close hemodynamic monitor Maintain SBP < 120 mmHg ongoing medical Tx Close hemodynamic monitor Maintain SBP < 120 mmHg Complication requiring Operative or Intervational management Malperfusion syndrome Progression of dissection Aneurysm expansion Uncontrolled hypertension Yes dissection involving the ascending aorta Step 4 No Transition to oral medicine out patient disease surveillance imagine

28. Recommendation for Medical Treatment of Patients With Thoracic Aortic Diseases Class I 1. Stringent control of hypertension, lipid profile optimization,smoking cessation, and other atherosclerosisrisk-reduction measures should be instituted forpatients with small aneurysms not requiring surgery,as well as for patients who are not onsideredto be surgical or stent graft candidates.

29. Recommendation for Medical Treatment of Patients With Thoracic Aortic Diseases Recommendations for Blood Pressure Control Class I 1. Antihypertensive therapy should be administered tohypertensive patients with thoracic aortic diseases toachieve a goal of less than 140/90 mm Hg (patientswithout diabetes) or less than 130/80 mm Hg (patientswith diabetes or chronic renal disease) toreduce the risk of stroke, myocardial infarction,heart failure, and cardiovascular death. 2. Beta adrenergic– blocking drugs should be administeredto all patients with Marfan syndrome andaortic aneurysm to reduce the rate of aortic dilatationunless contraindicated.

30. Recommendation for Medical Treatment of Patients With Thoracic Aortic Diseases Recommendations for Blood Pressure Control Class IIa 1. For patients with thoracic aortic aneurysm, it isreasonable to reduce blood pressure with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers89,413 to the lowest point patients can tolerate without adverse effects. 2. An angiotensin receptor blocker (losartan) is reasonablefor patients with Marfan syndrome, to reducethe rate of aortic dilatation unless contraindicated

31. Recommendation for Medical Treatment of Patients With Thoracic Aortic Diseases Recommendation for Dyslipidemia Class IIa 1. Treatment with a statin to achieve a target LDL cholesterol of less than 70 mg/dL is reasonable for patients with a coronary heart disease risk equivalent such as noncoronary atherosclerotic disease, atherosclerotic aortic aneurysm, and coexistent coronary heart disease at high risk for coronary ischemic events Recommendation for Smoking Cessation Class I 1. Smoking cessation and avoidance of exposure toenvironmental tobacco smoke at work and home are recommended. Follow-up, referral to special programs, and/or pharmacotherapy (including nicotine replacement, buproprion, or varenicline) is useful, as is adopting a stepwise strategy imed at smoking cessation (the 5 A’s are Ask, Advise, Assess, Assist, and Arrange

34. Recommendations for Preoperative Evaluation Class I 1. In preparation for sx, imaging studies  extent of disease and planned procedure. (Level of Evidence: C) 2. Pts with thoracic aortic dis. requiring a sx or catheter-based intervention who have symptoms or other findings of myocardial ischemia should Ix : significant CAD (Level of Evidence: C) 3. Pts with unstable coronary syndromes and significant CAD should undergo revascularization prior to or at the time of thoracic aortic sx or endovascular intervention with percutaneous coronary intervention or concomitant CABG. (Level of Evidence: C)

35. Recommendations for Preoperative Evaluation Class 2 a 1. Additional testing is reasonable pulmonary function tests, cardiac catheterization, aortography, 24-hour Holter monitoring, noninvasive carotid artery screening, brain imaging, echocardiography, and neurocognitive testing. (Level of Evidence: C) 2. For patients who are to undergo surgery for ascending or arch aortic disease, and who have clinically stable, but significant (flow limiting), CAD it is reasonable to perform concomitant CABG (Level of Evidence: C)

36. Recommendations for Preoperative Evaluation Class 2 b 1. For pts who are to undergo surgery or endovascular intervention for descending thoracic aortic disease, and who have clinically stable, but significant (flow limiting), CAD, the benefits of coronary revascularization are not well established. (Level of Evidence: B)